Company intelligence / Profile preview
Phio Pharmaceuticals
- Ownership
- Public · PHIO
- Employees
- ~5
- Development stage
- Phase 1
Overview
Phio’s lead candidate, PH‑762, uses its proprietary INTASYL® self-delivering siRNA platform to silence immune checkpoint genes in tumors. In a Phase 1b trial for advanced skin cancers including cSCC and melanoma, initial results show promising safety and efficacy signals. In the second dose cohort for cSCC patients, two achieved complete response with full tumor clearance at Day 36 post-treatment; one had a partial response (~90% clearance), and another maintained stable disease. The first cohort also showed stable disease outcomes. Dose escalation has been approved by an independent safety committee based on these results.[4]
- Therapeutic areas
- Oncology
- Modalities
- RNA interference (RNAi)siRNA (small interfering RNA)Self-delivering RNAi compounds ("sd-rxRNA")
- Industry
- Biotech
Drug pipeline
12 assets11 more assets in the full pipeline.
Request access →Partnerships
Financials
- Market cap
- $12M
- Total revenue
- $0
- Enterprise value
- $-1M
Beyond the preview
Go deeper on Phio Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Phio Pharmaceuticals.